MERKEL CELL CARCINOMA
Clinical trials for MERKEL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new MERKEL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for MERKEL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo therapy shows promise in advanced cancers, but trial halted early
Disease control TerminatedThis study tested whether injecting vidutolimod directly into tumors plus giving cemiplimab through a vein could shrink cancers that have spread. The trial included 77 people with several types of advanced cancer. Unfortunately, the study was stopped early, so we have less inform…
Matched conditions: MERKEL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Experimental cancer combo shows early promise but study halted
Disease control TerminatedThis early-phase trial tested a new drug called nanrilkefusp alfa, which helps activate immune cells, both alone and combined with the immunotherapy pembrolizumab. It included 115 people with various advanced solid tumors that had stopped responding to standard treatments. The st…
Matched conditions: MERKEL CELL CARCINOMA
Phase: PHASE1 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Promising cancer combo trial halted after just 2 patients
Disease control TerminatedThis early-phase study tested a radioactive drug called 225Ac-SSO110 combined with standard immune checkpoint inhibitors for people with advanced small cell lung cancer or Merkel cell carcinoma. The goal was to check safety and find the right dose. However, the trial was terminat…
Matched conditions: MERKEL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Ariceum Therapeutics GmbH • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New cancer drug OC-001 tested in advanced tumors – trial ends early
Disease control TerminatedThis early-phase trial tested an experimental drug called OC-001, given alone or with the immunotherapy avelumab, in 73 people with various advanced or metastatic cancers (like lung, breast, and bladder cancer). The main goals were to check safety and how the drug moves through t…
Matched conditions: MERKEL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Ocellaris Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Cancer-Fighting virus injected directly into tumors shows promise in early trial
Disease control TerminatedThis early-phase trial tested a new treatment called BT-001, a virus designed to infect and kill cancer cells, given alone or with the immunotherapy drug pembrolizumab. The study involved 31 people with advanced solid tumors like melanoma, lung cancer, or sarcoma that had spread.…
Matched conditions: MERKEL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Transgene • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Experimental combo for skin cancer shows early promise but study halted
Disease control TerminatedThis study tested whether adding an immune-boosting drug (NT-I7) to a standard immunotherapy (atezolizumab) could help people with advanced skin cancers like melanoma, Merkel cell carcinoma, and squamous cell carcinoma. The trial included 31 adults whose cancer had not responded …
Matched conditions: MERKEL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cancer drug trial ends early
Disease control TerminatedThis early-stage study tested an experimental drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are…
Matched conditions: MERKEL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC